These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 18627336

  • 1. Imiglucerase and its use for the treatment of Gaucher's disease.
    Weinreb NJ.
    Expert Opin Pharmacother; 2008 Aug; 9(11):1987-2000. PubMed ID: 18627336
    [Abstract] [Full Text] [Related]

  • 2. Gaucher's disease: a review.
    Morales LE.
    Ann Pharmacother; 1996 Apr; 30(4):381-8. PubMed ID: 8729893
    [Abstract] [Full Text] [Related]

  • 3. Imiglucerase treatment in Gaucher's disease.
    Shah U, Nadeem N, Husen Y, Fadoo Z.
    J Ayub Med Coll Abbottabad; 2007 Apr; 19(2):56-9. PubMed ID: 18183722
    [Abstract] [Full Text] [Related]

  • 4. First long-term results of imiglucerase therapy of type 1 Gaucher disease.
    Niederau C, vom Dahl S, Häussinger D.
    Eur J Med Res; 1998 Feb 21; 3(1-2):25-30. PubMed ID: 9512964
    [Abstract] [Full Text] [Related]

  • 5. Replacement therapy with imiglucerase for type 1 Gaucher's disease.
    Zimran A, Elstein D, Levy-Lahad E, Zevin S, Hadas-Halpern I, Bar-Ziv Y, Foldes J, Schwartz AJ, Abrahamov A.
    Lancet; 1995 Jun 10; 345(8963):1479-80. PubMed ID: 7769903
    [Abstract] [Full Text] [Related]

  • 6. Alglucerase. A review of its therapeutic use in Gaucher's disease.
    Whittington R, Goa KL.
    Drugs; 1992 Jul 10; 44(1):72-93. PubMed ID: 1379912
    [Abstract] [Full Text] [Related]

  • 7. Improvement In Symptoms Of Gaucher's Disease By Enzyme Replacement Therapy.
    Mazher W, Ali J, Abubakar S, Basar S, Murtaza G.
    J Ayub Med Coll Abbottabad; 2018 Jul 10; 30(3):479-481. PubMed ID: 30465391
    [Abstract] [Full Text] [Related]

  • 8. Taliglucerase alfa for the treatment of Gaucher's disease.
    Haddley K.
    Drugs Today (Barc); 2012 Aug 10; 48(8):525-32. PubMed ID: 22916340
    [Abstract] [Full Text] [Related]

  • 9. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.
    Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, Vom Dahl S, Elstein D, Erikson A, Giralt M, Heitner R, Hollak C, Hrebicek M, Lewis S, Mehta A, Pastores GM, Rolfs A, Miranda MC, Zimran A, Advisory Council to the European Working Group on Gaucher Disease.
    J Inherit Metab Dis; 2003 Aug 10; 26(6):513-26. PubMed ID: 14605497
    [Abstract] [Full Text] [Related]

  • 10. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
    Prescrire Int; 2005 Oct 10; 14(79):168-70. PubMed ID: 16285070
    [Abstract] [Full Text] [Related]

  • 11. Gaucher's disease in Lithuania: its diagnosis and treatment.
    Kleinotienė G, Tylki-Szymanska A, Czartoryska B.
    Medicina (Kaunas); 2011 Oct 10; 47(7):405-11. PubMed ID: 22112991
    [Abstract] [Full Text] [Related]

  • 12. [Neurological manifestations of type 1 Gaucher's disease: Is a revision of disease classification needed?].
    Chérin P, Sedel F, Mignot C, Schupbach M, Gourfinkel-An I, Verny M, Baumann N.
    Rev Neurol (Paris); 2006 Nov 10; 162(11):1076-83. PubMed ID: 17086144
    [Abstract] [Full Text] [Related]

  • 13. Gaucher's disease: a review for the internist and hepatologist.
    Niederau C, Häussinger D.
    Hepatogastroenterology; 2000 Nov 10; 47(34):984-97. PubMed ID: 11020862
    [Abstract] [Full Text] [Related]

  • 14. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
    Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC.
    Lancet; 2015 Jun 13; 385(9985):2355-62. PubMed ID: 25819691
    [Abstract] [Full Text] [Related]

  • 15. Enzyme replacement therapy for Gaucher's disease.
    Beutler E.
    Baillieres Clin Haematol; 1997 Dec 13; 10(4):751-63. PubMed ID: 9497862
    [Abstract] [Full Text] [Related]

  • 16. [Gaucher's disease and imiglucerase in 2009/2010: what leads to a suddenly enforced prioritisation?].
    Hofstetter K, Raspe H, Stumpf S, Framke S.
    Gesundheitswesen; 2015 Feb 13; 77(2):86-92. PubMed ID: 24671892
    [Abstract] [Full Text] [Related]

  • 17. [Safety of use of velaglucerase in 2 patients with type 1 Gaucher's disease].
    Latre P, Giraldo P.
    Med Clin (Barc); 2011 Sep 13; 137 Suppl 1():39-42. PubMed ID: 22230124
    [Abstract] [Full Text] [Related]

  • 18. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE.
    N Engl J Med; 1991 May 23; 324(21):1464-70. PubMed ID: 2023606
    [Abstract] [Full Text] [Related]

  • 19. Gaucher's disease in pregnancy.
    Rosnes JS, Sharkey MF, Veille JC, Mueller-Heubach E.
    Obstet Gynecol Surv; 1996 Sep 23; 51(9):549-58. PubMed ID: 8873155
    [Abstract] [Full Text] [Related]

  • 20. Individualization of long-term enzyme replacement therapy for Gaucher disease.
    Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, International Collaborative Gaucher Group U.S. Regional Coordinators.
    Genet Med; 2005 Feb 23; 7(2):105-10. PubMed ID: 15714077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.